These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38833173)

  • 21. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
    Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
    Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Argininosuccinate Synthetase-1 (ASS1) Loss in High-Grade Neuroendocrine Carcinomas of the Urinary Bladder: Implications for Targeted Therapy with ADI-PEG 20.
    Gupta S; Sahu D; Bomalaski JS; Frank I; Boorjian SA; Thapa P; Cheville JC; Hansel DE
    Endocr Pathol; 2018 Sep; 29(3):236-241. PubMed ID: 29453600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Small cell neuroendocrine carcinoma of the urinary bladder].
    Milica CR; Dragan MB; Aleksandar VM; Cane TDz; Dundjerović DM; Vjestica JM; Jasmina ML
    Acta Chir Iugosl; 2013; 60(1):95-7. PubMed ID: 24669571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential.
    Wang CC; Huang CY; Jhuang YL; Chen CC; Jeng YM
    Histopathology; 2018 Apr; 72(5):795-803. PubMed ID: 29193225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TERT promoter mutation analysis as a surrogate to morphology and immunohistochemistry in problematic spindle cell lesions of the urinary bladder.
    Bertz S; Stöhr R; Gaisa NT; Wullich B; Hartmann A; Agaimy A
    Histopathology; 2020 Dec; 77(6):949-962. PubMed ID: 32645760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small cell neuroendocrine carcinoma of the urinary bladder. A clinicopathologic study with emphasis on cytologic features.
    Ali SZ; Reuter VE; Zakowski MF
    Cancer; 1997 Jan; 79(2):356-61. PubMed ID: 9010109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beyond "Triton": Malignant Peripheral Nerve Sheath Tumors With Complete Heterologous Rhabdomyoblastic Differentiation Mimicking Spindle Cell Rhabdomyosarcoma.
    Hornick JL; Nielsen GP
    Am J Surg Pathol; 2019 Oct; 43(10):1323-1330. PubMed ID: 31107719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population.
    Siraj AK; Bu R; Iqbal K; Parvathareddy SK; Siraj N; Siraj S; Diaz MRF; Rala DR; Benito AD; Sabido MA; Al-Rasheed M; Al-Obaisi KAS; Al-Haqawi W; Victoria IG; Al Balawy W; Abedalthagafi M; Wakil SM; Ajarim D; Mohammed S; Alhussain T; Tulbah A; Al-Badawi IA; Al-Dayel F; Al-Kuraya KS
    Genomics; 2020 Mar; 112(2):1746-1753. PubMed ID: 31669704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.
    Cheng L; Davidson DD; Wang M; Lopez-Beltran A; Montironi R; Wang L; Tan PH; MacLennan GT; Williamson SR; Zhang S
    Histopathology; 2016 Jul; 69(1):107-13. PubMed ID: 26679899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
    Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D
    Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma.
    Nguyen D; Taheri D; Springer S; Cowan M; Guner G; Mendoza Rodriguez MA; Wang Y; Kinde I; VandenBussche CJ; Olson MT; Ricardo BF; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
    Virchows Arch; 2016 Oct; 469(4):427-34. PubMed ID: 27520411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.
    Kinde I; Munari E; Faraj SF; Hruban RH; Schoenberg M; Bivalacqua T; Allaf M; Springer S; Wang Y; Diaz LA; Kinzler KW; Vogelstein B; Papadopoulos N; Netto GJ
    Cancer Res; 2013 Dec; 73(24):7162-7. PubMed ID: 24121487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human Papilloma Virus 18-Positive Submucosal Small Cell Neuroendocrine Carcinoma of the Vagina: An Immunohistochemical and Genomic Study.
    Kitazono I; Akahane T; Sakihama M; Yanazume S; Matsushita M; Tabata K; Kobayashi Y; Kobayashi H; Umekita Y; Tanimoto A
    Int J Surg Pathol; 2021 Dec; 29(8):870-876. PubMed ID: 33792412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics.
    Cessna MH; Zhou H; Perkins SL; Tripp SR; Layfield L; Daines C; Coffin CM
    Am J Surg Pathol; 2001 Sep; 25(9):1150-7. PubMed ID: 11688574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.
    Rachakonda PS; Hosen I; de Verdier PJ; Fallah M; Heidenreich B; Ryk C; Wiklund NP; Steineck G; Schadendorf D; Hemminki K; Kumar R
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17426-31. PubMed ID: 24101484
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Weyerer V; Eckstein M; Strissel PL; Wullweber A; Lange F; Tögel L; Geppert CI; Sikic D; Taubert H; Wach S; Wullich B; Hartmann A; Stoehr R; Giedl J
    Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33562516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular characterization of a bladder pleomorphic rhabdomyosarcoma in an adult patient.
    Feroce F; Cantile M; Aquino G; Collina F; Scognamiglio G; Castaldo L; Perdonà S; Botti G; De Chiara A
    Pathol Res Pract; 2020 Aug; 216(8):153033. PubMed ID: 32703497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical features and hypoxic marker expression of primary sinonasal and laryngeal small-cell neuroendocrine carcinoma: a small case series.
    Chai L; Ying HF; Wu TT; Zhou SH; Bao YY; Yao HT; You QH
    World J Surg Oncol; 2014 Jul; 12():199. PubMed ID: 24980293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clonal Origin and Lineage Ambiguity in Mixed Neuroendocrine Carcinoma of the Uterine Cervix.
    Masuda M; Iida K; Iwabuchi S; Tanaka M; Kubota S; Uematsu H; Onuma K; Kukita Y; Kato K; Kamiura S; Nakajima A; Coppo R; Kanda M; Yoshino K; Ueda Y; Morii E; Kimura T; Kondo J; Okada-Hatakeyama M; Hashimoto S; Inoue M
    Am J Pathol; 2024 Mar; 194(3):415-429. PubMed ID: 38103888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder.
    Cowan ML; Springer S; Nguyen D; Taheri D; Guner G; Mendoza Rodriguez MA; Wang Y; Kinde I; Del Carmen Rodriguez Pena M; VandenBussche CJ; Olson MT; Cunha I; Fujita K; Ertoy D; Kinzler K; Bivalacqua T; Papadopoulos N; Vogelstein B; Netto GJ
    Hum Pathol; 2016 Jul; 53():8-13. PubMed ID: 26980028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.